Marit Sletten

  • Research Engineer; BSc
 

Publications 2024

Iversen N, Henriksson CE, Sletten M, Le MS, Lindberg BR, Andersen R, Paus B (2024)
Heterozygosity for the Budapest 3 mutation in SERPINC1 in a family with thrombophilia and structural anomalies of the inferior vena cava
Thromb J, 22 (1), 75
DOI 10.1186/s12959-024-00644-1, PubMed 39129027

Lind SM, Sletten M, Hellenes M, Mathelier A, Tekpli X, Tinholt M, Iversen N (2024)
Coagulation factor V in breast cancer: a p53-regulated tumor suppressor and predictive marker for treatment response to chemotherapy
J Thromb Haemost, 22 (6), 1569-1582
DOI 10.1016/j.jtha.2024.02.008, PubMed 38382738

Publications 2021

Andersen E, Chollet ME, Sletten M, Stavik B, Skarpen E, Backe PH, Thiede B, Glosli H, Henriksson CE, Iversen N (2021)
Molecular Characterization of Two Homozygous Factor VII Variants Associated with Intracranial Bleeding
Thromb Haemost, 121 (12), 1588-1598
DOI 10.1055/a-1450-8568, PubMed 33742435

Andresen MS, Sletten M, Sandset PM, Iversen N, Stavik B, Tinholt M (2021)
Coagulation Factor V (F5) is an Estrogen-Responsive Gene in Breast Cancer Cells
Thromb Haemost, 122 (8), 1288-1295
DOI 10.1055/a-1707-2130, PubMed 34826880

Publications 2020

Andresen MS, Stavik B, Sletten M, Tinholt M, Sandset PM, Iversen N, Skretting G (2020)
Indirect regulation of TFPI-2 expression by miR-494 in breast cancer cells
Sci Rep, 10 (1), 4036
DOI 10.1038/s41598-020-61018-x, PubMed 32132611

Publications 2015

Tinholt M, Stavik B, Louch W, Carlson CR, Sletten M, Ruf W, Skretting G, Sandset PM, Iversen N (2015)
Syndecan-3 and TFPI colocalize on the surface of endothelial-, smooth muscle-, and cancer cells
PLoS One, 10 (1), e0117404
DOI 10.1371/journal.pone.0117404, PubMed 25617766

Publications 2014

Askautrud HA, Gjernes E, Gunnes G, Sletten M, Ross DT, Børresen-Dale AL, Iversen N, Tranulis MA, Frengen E (2014)
Global gene expression analysis reveals a link between NDRG1 and vesicle transport
PLoS One, 9 (1), e87268
DOI 10.1371/journal.pone.0087268, PubMed 24498060

Publications 2013

Stavik B, Tinholt M, Sletten M, Skretting G, Sandset PM, Iversen N (2013)
TFPIα and TFPIβ are expressed at the surface of breast cancer cells and inhibit TF-FVIIa activity
J Hematol Oncol, 6, 5
DOI 10.1186/1756-8722-6-5, PubMed 23320987

Publications 2012

Stavik B, Skretting G, Olstad OK, Sletten M, Dehli Vigeland M, Sandset PM, Iversen N (2012)
TFPI alpha and beta regulate mRNAs and microRNAs involved in cancer biology and in the immune system in breast cancer cells
PLoS One, 7 (10), e47184
DOI 10.1371/journal.pone.0047184, PubMed 23071754

Publications 2011

Stavik B, Skretting G, Aasheim HC, Tinholt M, Zernichow L, Sletten M, Sandset PM, Iversen N (2011)
Downregulation of TFPI in breast cancer cells induces tyrosine phosphorylation signaling and increases metastatic growth by stimulating cell motility
BMC Cancer, 11, 357
DOI 10.1186/1471-2407-11-357, PubMed 21849050

Publications 2010

Stavik B, Skretting G, Sletten M, Sandset PM, Iversen N (2010)
Overexpression of both TFPIα and TFPIβ induces apoptosis and expression of genes involved in the death receptor pathway in breast cancer cells
Mol Carcinog, 49 (11), 951-63
DOI 10.1002/mc.20679, PubMed 20886581

Publications 2005

Teivainen-Laedre PA, Eliassen KA, Sletten M, Smith AJ, Berg K (2005)
Reduced LPA expression after peroxisome proliferator-activated receptor alpha (PPARalpha) activation in LPA-YAC transgenic mice
Pathophysiology, 11 (4), 201-208
DOI 10.1016/j.pathophys.2004.12.002, PubMed 15837165

Publications 2004

Djurovic S, Kristansen H, Sletten M, Halvorsen K, Berg K (2004)
Variations in transfection efficiency of VEGF165 and VEGF121-cDNA: its effects on proliferation and migration of human endothelial cells
Mol Biotechnol, 26 (1), 7-16
DOI 10.1385/MB:26:1:7, PubMed 14734819